Replies to post #186915 on Biotech Values

[ciotera]

Re: BMY HCV Japan

I'm not surprised that the first all-oral regimen does well in the absence of any competition in a country that has very old (IFN-ineligible) HCV population. But that won't necessarily carry over to subsequent entrants.